CD274 and non-small cell lung carcinoma: And third, albeit the association of the TRN signature with anti-PD-L1 treatment failure was analyzed using transcriptomic data for patients with NSCLC, prospective studies are required to show that the TRN signature indeed represents a bona fide anti-PD-L1 therapy outcome-predicting marker rather than being a negative prognostic marker.